Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess the antitumor efficacy of single-agent brentuximab vedotin (1.8 mg/kg administered intravenously every 3 weeks) as measured by the overall objective response rate (ORR) in patients with relapsed or refractory sALCL following at least 1 multiagent chemotherapy (CHOP or equivalent multiagent chemotherapy regimens with curative intent)
Inclusion criteria
- Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma